Matrion Decellularized Placental Membrane Versus Conventional Wound Management in Subjects With Diabetic Foot Ulcers

Recruiting now · Not applicable

Conditions studied: Diabetic Foot Ulcer (DFU), Lower Extremity

In brief

This study will evaluate Matrion™ (LifeNet Health, Inc., Virginia Beach, VA), a placental membrane product, as a treatment for diabetic foot ulcers compared to conventional wound care. Matrion is derived from donated human birth tissue and includes both the amniotic and chorionic layers, along with the trophoblast layer. It is minimally processed using a proprietary decellularization method and terminally sterilized to ensure the membrane is acellular and sterile, making it suitable for surgical applications.

Key facts

Study ID: NCT07116876
Run by: LifeNet Health
People needed: 120
Starts: 2025-06-26
Expected to finish: 2026-06-01
Last updated by the study team: 2025-12-10

Who can join

Age: 21 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

To be considered eligible to participate in this study, a subject must meet the inclusion criteria listed below:
Be male or female and aged between 21 and 80 years at the time of informed consent
Have a diagnosis of Type I or Type II diabetes as defined by the American Diabetes Association and have been on a stable anti-diabetic treatment regimen for at least 30 days before the baseline visit.
Have full-thickness wound of the lower extremity, below the ankle
Have a single target ulcer
Have a wound with an area greater than or equal to 1cm2 and less than 25 cm2 with a depth less than or equal to 9 mm
Have a diabetic foot ulcer that has been present for at least 30 days with a Wagner Classification Grade 1 or 2:
Grade 1: superficial diabetic ulcer involving the full skin thickness but not underlying tissues
Grade 2: ulcer extension involving ligament, tendon, joint capsule, or fascia, without presence of abscess or osteomyelitis
Have an absence of infection based on Infectious Disease Society of America criteria (assessed at BOTH Screening/Visit 1 and Baseline/Visit 2)
Have an adequate circulation to the affected lower extremity, defined as at least one of the criteria within the previous 60 days:
Transcutaneous oxygen measurement at the dorsum of the foot greater or equal to 30 mm Hg
Ankle-brachial index (ABI) ranging from 0.8 to 1.2
At least biphasic Doppler arterial waveforms at the dorsalis pedis and posterior tibial arteries
Have the ability to comply with off-loading and dressing change requirements
Have the ability to understand the requirements of the study, have provided written informed consent as evidenced by signature on an informed consent form (ICF) approved by an institutional review board (IRB), and agree to abide by the study restrictions and return to the site for the required assessments
Have provided written authorization for use and disclosure of protected health information
Have a life expectancy of greater than 6 months

You may not qualify if…

To be eligible for entry into the study, the subject must not meet any of the exclusion criteria listed below:
Be pregnant or lactating
Subjects with a target wound <30 days old at Screening whose wound area has decreased in size ≥50% between the Screening and Baseline Visits (assessed at Baseline/Visit 2)
Have a circulating hemoglobin A1c exceeding 12% within 90 days of the Screening Visit (assessed at Screening/Visit 1 for subjects with labs collected <30 days of screening; assessed at Baseline/Visit 2 for subjects with labs collected at screening)
Have a serum creatinine concentration of 3.0 mg/dL or greater within 30 days prior to screening (assessed at Screening/Visit 1 for subjects with labs collected <30 days of screening; assessed at Baseline/Visit 2 for subjects with labs collected at screening)
Have a sensitivity to either of the following antibiotics: lincomycin, gentamicin, polymyxin B, or vancomycin
Have a sensitivity to polysorbate 20, N-lauroyl sarcosinate, benzonase or glycerol
Have the wound treated with biomedical or topical growth factors within the previous 30 days before the Screening Visit
Need for any additional concomitant dressing material other than the ones approved for this study
Have clinical signs of an infection at the study ulcer site (assessed at BOTH Screening/Visit 1 and Baseline/Visit 2)
Have the inability to tolerate an off-loading boot
Have a known or suspected disease of the immune system
Have an active or untreated malignancy or active, uncontrolled connective tissue disease
Had a treatment with immunosuppressive or chemotherapeutic agents, radiotherapy or systemic corticosteroids less than 30 days before the Baseline Visit
Have presence of necrosis, purulence, or sinus tracts that cannot be removed by debridement (assessed at Baseline/Visit 2)
Has undergone a revascularization procedure aimed at increasing blood flow in the treatment target limb less than 4 weeks before the Baseline Visit
Have serum aspartate aminotransferase, alanine aminotransferase, or alkaline phosphatase levels greater than three times the normal upper limit within 30 days prior to screening (assessed at Screening/Visit 1 if subject had labs collected <30 days of screening; assessed at Baseline/Visit 2 if subject had labs collected at screening)
Have active Charcot disease
Have undergone treatment with a living skin equivalent within the last 4 weeks before screening
Have ongoing evidence of peripheral vascular disease, including greater than one nonpalpable pulse on either foot
Have the presence of any condition that in the opinion of the investigator places the subject at undue risk or potentially jeopardizes the quality of the data to be generated

Where it is running

Compass Medical Research Center — Tucson, Arizona, United States (enrolling)
Bay Area Foot Care — Castro Valley, California, United States (enrolling)
Limb Preservaion Platform, Inc. — Fresno, California, United States (enrolling)
Center for Clinical Research, Inc — San Francisco, California, United States (enrolling)
Bay Area Foot Care — San Francisco, California, United States (enrolling)
ILD Research Center — Vista, California, United States (enrolling)
Humanity Clinical Research, Corp — Aventura, Florida, United States (enrolling)
South Florida Podiatry — Deerfield Beach, Florida, United States (enrolling)
Dinamo Research & Diagnostic Center, LLC — Hialeah, Florida, United States (enrolling)
Doctors Research Network, Inc. — Miami, Florida, United States (enrolling)
Independent Clinical Research — Decatur, Illinois, United States (enrolling)
Independent Clinical Research, LLC — Springfield, Illinois, United States (enrolling)
US Foot and Ankle Specialists — Raleigh, North Carolina, United States (enrolling)
Foot and Ankle Institute of the Carolinas — Rocky Mount, North Carolina, United States (enrolling)
Olympus Clinical Research — Katy, Texas, United States (enrolling)
Element Research Group — San Antonio, Texas, United States (enrolling)
Olympus-Alcanza — Sugar Land, Texas, United States (enrolling)
Foot and Ankle Specialists of the Mid-Atlantic — Salem, Virginia, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.